Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin

Seung Don Baek, Sun Joo Jang, So Eun Park, Tae Jin Ok, Jaechan Leem, Ho Su Lee, So Jung Park, Tae Hee Kim

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


HMG-CoA reductase inhibitors (statins) are widely used to treat hypercholesterolemia. Among the adverse effects associated with these drugs are statin-associated myopathies, ranging from asymptomatic elevation of serum creatine kinase to fatal rhabdomyolysis. Fluvastatin-induced fatal rhabdomyolysis has not been previously reported. We describehere a patient with liver cirrhosis who experienced fluvastatin-induced fatalrhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronaryartery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. Hewas also taking aspirin, betaxolol, candesartan, lactulose, and entecavir. Rhabdomyolysiswas complicated and continued to progress. He was treated with massive hydration, urinealkalization, intravenous furosemide, and continuous renal replacement therapy for acuterenal failure, but eventually died due to rhabdomyolysis complicated by hepatic failure. Inconclusion, fluvastatin should be used with caution in patients with liver cirrhosis, especially with other medications metabolized with CYP2C9.

Original languageEnglish
Pages (from-to)1634-1637
Number of pages4
JournalJournal of Korean Medical Science
Issue number12
StatePublished - Dec 2011


  • Fluvastatin
  • Liver cirrhosis
  • Rhabdomyolysis
  • Simvastatin


Dive into the research topics of 'Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin'. Together they form a unique fingerprint.

Cite this